{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:09:11Z","timestamp":1789949351167,"version":"4.0.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Estate of Pamela Miles"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00280-018-3614-8","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T01:35:37Z","timestamp":1528248937000},"page":"1-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Interactions of lean soft-tissue and chemotherapy toxicities in patients receiving anti-cancer treatments"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8282-6663","authenticated-orcid":false,"given":"Jessica J.","family":"Hopkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2640-3620","authenticated-orcid":false,"given":"Michael B.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"3614_CR1","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D Du Bois","year":"1916","unstructured":"Du Bois D, Du Bois E (1916) A formula to estimate the approximate surface area if height and weight are known. Arch Intern Med 17:863\u2013871","journal-title":"Arch Intern Med"},{"issue":"17","key":"3614_CR2","first-page":"1098","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD (1987) Simplified calculation of body-surface area. N Engl J Med 317(17):1098","journal-title":"N Engl J Med"},{"key":"3614_CR3","first-page":"225","volume":"54","author":"E Gehan","year":"1970","unstructured":"Gehan E, George S (1970) Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225\u2013235","journal-title":"Cancer Chemother Rep"},{"issue":"3","key":"3614_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/j.1475-097X.2006.00718.x","volume":"27","author":"JG Heaf","year":"2007","unstructured":"Heaf JG (2007) The origin of the 1\u2009\u00d7\u200973-m2 body surface area normalization: problems and implications. Clin Physiol Funct Imaging 27(3):135\u2013137. \n                    https:\/\/doi.org\/10.1111\/j.1475-097X.2006.00718.x","journal-title":"Clin Physiol Funct Imaging"},{"issue":"6","key":"3614_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1152\/japplphysiol.00744.2004","volume":"97","author":"W Shen","year":"2004","unstructured":"Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol 97(6):2333\u20132338. \n                    https:\/\/doi.org\/10.1152\/japplphysiol.00744.2004","journal-title":"J Appl Physiol"},{"key":"3614_CR6","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33:997\u20131006","journal-title":"Appl Physiol Nutr Metab"},{"issue":"6","key":"3614_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1200\/JCO.2009.24.9730","volume":"28","author":"S Antoun","year":"2010","unstructured":"Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010) Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol 28(6):1054\u20131060. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.24.9730","journal-title":"J Clin Oncol"},{"issue":"6","key":"3614_CR8","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1210\/jc.2013-1115","volume":"98","author":"MH Massicotte","year":"2013","unstructured":"Massicotte MH, Borget I, Broutin S, Baracos VE, Leboulleux S, Baudin E, Paci A, Deroussent A, Schlumberger M, Antoun S (2013) Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study. J Clin Endocrinol Metab 98(6):2401\u20132408. \n                    https:\/\/doi.org\/10.1210\/jc.2013-1115","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"3614_CR9","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1038\/bjc.2012.144","volume":"106","author":"CM Prado","year":"2012","unstructured":"Prado CM, Bekaii-Saab T, Doyle LA, Shrestha S, Ghosh S, Baracos VE, Sawyer MB (2012) Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer 106(10):1583\u20131586. \n                    https:\/\/doi.org\/10.1038\/bjc.2012.144","journal-title":"Br J Cancer"},{"issue":"4","key":"3614_CR10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jcsm.12047","volume":"6","author":"F Moryoussef","year":"2015","unstructured":"Moryoussef F, Dhooge M, Volet J, Barbe C, Brezault C, Hoeffel C, Coriat R, Bouche O (2015) Reversible sarcopenia in patients with gastrointestinal stromal tumor treated with imatinib. J Cachexia Sarcopenia Muscle 6(4):343\u2013350. \n                    https:\/\/doi.org\/10.1002\/jcsm.12047","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"3614_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","volume":"6","author":"C Yip","year":"2015","unstructured":"Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V (2015) Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights Imaging 6(4):489\u2013497. \n                    https:\/\/doi.org\/10.1007\/s13244-015-0414-0","journal-title":"Insights Imaging"},{"issue":"1","key":"3614_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.clnu.2011.08.008","volume":"31","author":"S Awad","year":"2012","unstructured":"Awad S, Tan BH, Cui H, Bhalla A, Fearon KC, Parsons SL, Catton JA, Lobo DN (2012) Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clin Nutr 31(1):74\u201377. \n                    https:\/\/doi.org\/10.1016\/j.clnu.2011.08.008","journal-title":"Clin Nutr"},{"issue":"2","key":"3614_CR13","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ejso.2016.11.015","volume":"43","author":"M Paireder","year":"2017","unstructured":"Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, Schoppmann SF (2017) Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. Eur J Surg Oncol 43(2):478\u2013484. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2016.11.015","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"3614_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.5230\/jgc.2017.17.e8","volume":"17","author":"C Palmela","year":"2017","unstructured":"Palmela C, Velho S, Agostinho L, Branco F, Santos M, Santos MP, Oliveira MH, Strecht J, Maio R, Cravo M, Baracos VE (2017) Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer. J Gastric Cancer 17(1):74\u201387. \n                    https:\/\/doi.org\/10.5230\/jgc.2017.17.e8","journal-title":"J Gastric Cancer"},{"key":"3614_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12267","author":"LE Daly","year":"2018","unstructured":"Daly LE, Ni Bhuachalla EB, Power DG, Cushen SJ, James K, Ryan AM (2018) Loss of skeletal muscle during systemic chemotherapy is prognostic of poor survival in patients with foregut cancer. J Cachexia Sarcopenia Muscle. \n                    https:\/\/doi.org\/10.1002\/jcsm.12267","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3614_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.breast.2016.10.014","volume":"31","author":"HN Rier","year":"2017","unstructured":"Rier HN, Jager A, Sleijfer S, van Rosmalen J, Kock MC, Levin MD (2017) Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast 31:9\u201315. \n                    https:\/\/doi.org\/10.1016\/j.breast.2016.10.014","journal-title":"Breast"},{"key":"3614_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2018.03.002","author":"AJ Benjamin","year":"2018","unstructured":"Benjamin AJ, Buschmann MM, Zhang SQ, Wroblewski K, Kindler HL, Roggin KK, Dale W (2018) The impact of changes in radiographic sarcopenia on overall survival in older adults undergoing different treatment pathways for pancreatic cancer. J Geriatr Oncol. \n                    https:\/\/doi.org\/10.1016\/j.jgo.2018.03.002","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"3614_CR18","doi-asserted-by":"publisher","first-page":"e0169136","DOI":"10.1371\/journal.pone.0169136","volume":"12","author":"J Nattenmuller","year":"2017","unstructured":"Nattenmuller J, Wochner R, Muley T, Steins M, Hummler S, Teucher B, Wiskemann J, Kauczor HU, Wielputz MO, Heussel CP (2017) Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLoS One 12(1):e0169136. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0169136","journal-title":"PLoS One"},{"key":"3614_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2017.12.004","author":"MD Goncalves","year":"2018","unstructured":"Goncalves MD, Taylor S, Halpenny DF, Schwitzer E, Gandelman S, Jackson J, Lukose A, Plodkowski AJ, Tan KS, Dunphy M, Jones LW, Downey RJ (2018) Imaging skeletal muscle volume, density, and FDG uptake before and after induction therapy for non-small cell lung cancer. Clin Radiol. \n                    https:\/\/doi.org\/10.1016\/j.crad.2017.12.004","journal-title":"Clin Radiol"},{"key":"3614_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw145","author":"DY Xiao","year":"2016","unstructured":"Xiao DY, Luo S, O\u2019Brian K, Sanfilippo KM, Ganti A, Riedell P, Lynch RC, Liu W, Kahl BS, Cashen AF, Fehniger TA, Carson KR (2016) Longitudinal body composition changes in diffuse large B-cell lymphoma survivors: a retrospective cohort study of united states veterans. J Natl Cancer Inst. \n                    https:\/\/doi.org\/10.1093\/jnci\/djw145","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"3614_CR21","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/jcsm.12107","volume":"7","author":"IJ Rutten","year":"2016","unstructured":"Rutten IJ, van Dijk DP, Kruitwagen RF, Beets-Tan RG, Olde Damink SW, van Gorp T (2016) Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients. J Cachexia Sarcopenia Muscle 7(4):458\u2013466. \n                    https:\/\/doi.org\/10.1002\/jcsm.12107","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"3614_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/bjc.2016.431","volume":"116","author":"LE Daly","year":"2017","unstructured":"Daly LE, Power DG, O\u2019Reilly A, Donnellan P, Cushen SJ, O\u2019Sullivan K, Twomey M, Woodlock DP, Redmond HP, Ryan AM (2017) The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma. Br J Cancer 116(3):310\u2013317. \n                    https:\/\/doi.org\/10.1038\/bjc.2016.431","journal-title":"Br J Cancer"},{"key":"3614_CR23","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3892\/mco.2016.1015","volume":"5","author":"B Gyawali","year":"2016","unstructured":"Gyawali B, Shimokata T, Honda K, Kondoh C, Hayashi N, Yoshino Y, Sassa N, Nakano Y, Gotoh M, Ando Y (2016) Muscle wasting associated with long-term use of mTOR inhibitors. Mol Clin Oncol 5:641\u2013646","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"3614_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/bjc.2013.340","volume":"109","author":"C Pezaro","year":"2013","unstructured":"Pezaro C, Mukherji D, Tunariu N, Cassidy AM, Omlin A, Bianchini D, Seed G, Reid AH, Olmos D, de Bono JS, Attard G (2013) Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer 109(2):325\u2013331. \n                    https:\/\/doi.org\/10.1038\/bjc.2013.340","journal-title":"Br J Cancer"},{"issue":"10","key":"3614_CR25","doi-asserted-by":"publisher","first-page":"e0139749","DOI":"10.1371\/journal.pone.0139749","volume":"10","author":"Y Choi","year":"2015","unstructured":"Choi Y, Oh DY, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Bang YJ (2015) Skeletal muscle depletion predicts the prognosis of patients with advanced pancreatic cancer undergoing palliative chemotherapy, independent of body mass index. PLoS One 10(10):e0139749. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0139749","journal-title":"PLoS One"},{"issue":"8","key":"3614_CR26","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-08-2242","volume":"15","author":"CM Prado","year":"2009","unstructured":"Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 15(8):2920\u20132926. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2242","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3614_CR27","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.2013.58","volume":"108","author":"O Huillard","year":"2013","unstructured":"Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108(5):1034\u20131041. \n                    https:\/\/doi.org\/10.1038\/bjc.2013.58","journal-title":"Br J Cancer"},{"issue":"4","key":"3614_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/01635581.2014.894103","volume":"66","author":"M Barret","year":"2014","unstructured":"Barret M, Antoun S, Dalban C, Malka D, Mansourbakht T, Zaanan A, Latko E, Taieb J (2014) Sarcopenia is linked to treatment toxicity in patients with metastatic colorectal cancer. Nutr Cancer 66(4):583\u2013589. \n                    https:\/\/doi.org\/10.1080\/01635581.2014.894103","journal-title":"Nutr Cancer"},{"issue":"3","key":"3614_CR29","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00520-014-2418-6","volume":"23","author":"HW Jung","year":"2015","unstructured":"Jung HW, Kim JW, Kim JY, Kim SW, Yang HK, Lee JW, Lee KW, Kim DW, Kang SB, Kim KI, Kim CH, Kim JH (2015) Effect of muscle mass on toxicity and survival in patients with colon cancer undergoing adjuvant chemotherapy. Support Care Cancer 23(3):687\u2013694. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2418-6","journal-title":"Support Care Cancer"},{"issue":"3","key":"3614_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","volume":"41","author":"BH Tan","year":"2015","unstructured":"Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA (2015) Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol 41(3):333\u2013338. \n                    https:\/\/doi.org\/10.1016\/j.ejso.2014.11.040","journal-title":"Eur J Surg Oncol"},{"issue":"12","key":"3614_CR31","doi-asserted-by":"publisher","first-page":"3891","DOI":"10.1245\/s10434-016-5360-7","volume":"23","author":"S Chemama","year":"2016","unstructured":"Chemama S, Bayar MA, Lanoy E, Ammari S, Stoclin A, Goere D, Elias D, Raynard B, Antoun S (2016) Sarcopenia is associated with chemotherapy toxicity in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal cancer. Ann Surg Oncol 23(12):3891\u20133898. \n                    https:\/\/doi.org\/10.1245\/s10434-016-5360-7","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"3614_CR32","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, Nyrop KA, Williams GR, Nishijima TF, Benbow JM, Muss HB (2017) Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res 23(3):658\u2013665. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0940","journal-title":"Clin Cancer Res"},{"issue":"24","key":"3614_CR33","doi-asserted-by":"publisher","first-page":"4868","DOI":"10.1002\/cncr.30950","volume":"123","author":"EM Cespedes Feliciano","year":"2017","unstructured":"Cespedes Feliciano EM, Lee VS, Prado CM, Meyerhardt JA, Alexeeff S, Kroenke CH, Xiao J, Castillo AL, Caan BJ (2017) Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: the C-SCANS study. Cancer 123(24):4868\u20134877. \n                    https:\/\/doi.org\/10.1002\/cncr.30950","journal-title":"Cancer"},{"issue":"2","key":"3614_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00280-017-3487-2","volume":"81","author":"GR Williams","year":"2018","unstructured":"Williams GR, Deal AM, Shachar SS, Walko CM, Patel JN, O\u2019Neil B, McLeod HL, Weinberg MS, Choi SK, Muss HB, Sanoff HK (2018) The impact of skeletal muscle on the pharmacokinetics and toxicity of 5-fluorouracil in colorectal cancer. Cancer Chemother Pharmacol 81(2):413\u2013417. \n                    https:\/\/doi.org\/10.1007\/s00280-017-3487-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3614_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00280-010-1288-y","volume":"67","author":"CM Prado","year":"2011","unstructured":"Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB (2011) An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 67(1):93\u2013101. \n                    https:\/\/doi.org\/10.1007\/s00280-010-1288-y","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"3614_CR36","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-16-2266","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, Williams GR, Nyrop KA, Popuri K, Choi SK, Muss HB (2017) Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res 23(14):3537\u20133543. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2266","journal-title":"Clin Cancer Res"},{"issue":"7","key":"3614_CR37","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1470-2045(08)70153-0","volume":"9","author":"CMM Prado","year":"2008","unstructured":"Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE (2008) Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 9(7):629\u2013635. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(08)70153-0","journal-title":"Lancet Oncol"},{"issue":"4","key":"3614_CR38","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/cam4.621","volume":"5","author":"R Ali","year":"2016","unstructured":"Ali R, Baracos VE, Sawyer MB, Bianchi L, Roberts S, Assenat E, Mollevi C, Senesse P (2016) Lean body mass as an independent determinant of dose-limiting toxicity and neuropathy in patients with colon cancer treated with FOLFOX regimens. Cancer Med 5(4):607\u2013616. \n                    https:\/\/doi.org\/10.1002\/cam4.621","journal-title":"Cancer Med"},{"key":"3614_CR39","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/COC.0000000000000061","volume":"40","author":"SJ Cushen","year":"2017","unstructured":"Cushen SJ, Power DG, Teo MY, MacEneaney P, Maher MM, McDermott R, O\u2019Sullivan K, Ryan AM (2017) Body composition by computed tomography as a predictor of toxicity in patients with renal cell carcinoma treated with sunitinib. Am J Clin Oncol 40:47\u201352. \n                    https:\/\/doi.org\/10.1097\/COC.0000000000000061","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"3614_CR40","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7(5):e37563. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0037563","journal-title":"PLoS One"},{"issue":"3","key":"3614_CR41","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.clnu.2015.05.011","volume":"35","author":"P Anandavadivelan","year":"2016","unstructured":"Anandavadivelan P, Brismar TB, Nilsson M, Johar AM, Martin L (2016) Sarcopenic obesity: a probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients. Clin Nutr 35(3):724\u2013730. \n                    https:\/\/doi.org\/10.1016\/j.clnu.2015.05.011","journal-title":"Clin Nutr"},{"key":"3614_CR42","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.clnesp.2016.04.001","volume":"13","author":"SJ Cushen","year":"2016","unstructured":"Cushen SJ, Power DG, Murphy KP, McDermott R, Griffin BT, Lim M, Daly L, MacEneaney P, K OS, Prado CM, Ryan AM (2016) Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel. Clin Nutr ESPEN 13:e39\u2013e45. \n                    https:\/\/doi.org\/10.1016\/j.clnesp.2016.04.001","journal-title":"Clin Nutr ESPEN"},{"issue":"2","key":"3614_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10637-013-0053-6","volume":"32","author":"S Cousin","year":"2014","unstructured":"Cousin S, Hollebecque A, Koscielny S, Mir O, Varga A, Baracos VE, Soria JC, Antoun S (2014) Low skeletal muscle is associated with toxicity in patients included in phase I trials. Invest New Drugs 32(2):382\u2013387. \n                    https:\/\/doi.org\/10.1007\/s10637-013-0053-6","journal-title":"Invest New Drugs"},{"issue":"6","key":"3614_CR44","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1139\/apnm-2013-0403","volume":"39","author":"CM Prado","year":"2014","unstructured":"Prado CM, Baracos VE, Xiao J, Birdsell L, Stuyckens K, Park YC, Parekh T, Sawyer MB (2014) The association between body composition and toxicities from the combination of Doxil and trabectedin in patients with advanced relapsed ovarian cancer. Appl Physiol Nutr Metab 39(6):693\u2013698. \n                    https:\/\/doi.org\/10.1139\/apnm-2013-0403","journal-title":"Appl Physiol Nutr Metab"},{"issue":"2","key":"3614_CR45","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1080\/01635581.2012.638433","volume":"64","author":"HA Parsons","year":"2012","unstructured":"Parsons HA, Tsimberidou AM, Pontikos M, Fu S, Hong D, Wen S, Baracos VE, Kurzrock R (2012) Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer 64(2):206\u2013217. \n                    https:\/\/doi.org\/10.1080\/01635581.2012.638433","journal-title":"Nutr Cancer"},{"issue":"11","key":"3614_CR46","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1007\/s00520-016-3287-y","volume":"24","author":"D Srdic","year":"2016","unstructured":"Srdic D, Plestina S, Sverko-Peternac A, Nikolac N, Simundic AM, Samarzija M (2016) Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value. Support Care Cancer 24(11):4495\u20134502. \n                    https:\/\/doi.org\/10.1007\/s00520-016-3287-y","journal-title":"Support Care Cancer"},{"key":"3614_CR47","first-page":"5655","volume":"33","author":"S Gouerant","year":"2013","unstructured":"Gouerant S, Leheurteur M, Chaker M, Modezelewski R, Rigal O, Veyret C, Lauridant G, Clatot F (2013) A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res 33:5655\u20135662","journal-title":"Anticancer Res"},{"issue":"11","key":"3614_CR48","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/1078-0432.CCR-06-3067","volume":"13","author":"CM Prado","year":"2007","unstructured":"Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res 13(11):3264\u20133268. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3067","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3614_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.lungcan.2015.07.001","volume":"90","author":"B Sjoblom","year":"2015","unstructured":"Sjoblom B, Gronberg BH, Benth JS, Baracos VE, Flotten O, Hjermstad MJ, Aass N, Jordhoy M (2015) Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer. Lung Cancer 90(1):85\u201391. \n                    https:\/\/doi.org\/10.1016\/j.lungcan.2015.07.001","journal-title":"Lung Cancer"},{"issue":"8","key":"3614_CR50","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1634\/theoncologist.2015-0058","volume":"20","author":"O Arrieta","year":"2015","unstructured":"Arrieta O, De la Torre-Vallejo M, Lopez-Macias D, Orta D, Turcott J, Macedo-Perez EO, Sanchez-Lara K, Ramirez-Tirado LA, Baracos VE (2015) Nutritional status, body surface, and low lean body mass\/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer. Oncologist 20(8):967\u2013974. \n                    https:\/\/doi.org\/10.1634\/theoncologist.2015-0058","journal-title":"Oncologist"},{"key":"3614_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2016.09.008","author":"B Sjoblom","year":"2016","unstructured":"Sjoblom B, Benth JS, Gronberg BH, Baracos VE, Sawyer MB, Flotten O, Hjermstad MJ, Aass N, Jordhoy M (2016) Drug dose per kilogram lean body mass predicts hematologic toxicity from carboplatin-doublet chemotherapy in advanced non-small-cell lung cancer. Clin Lung Cancer. \n                    https:\/\/doi.org\/10.1016\/j.cllc.2016.09.008","journal-title":"Clin Lung Cancer"},{"issue":"12","key":"3614_CR52","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1200\/JCO.2012.45.2722","volume":"31","author":"L Martin","year":"2013","unstructured":"Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE (2013) Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 31(12):1539\u20131547. \n                    https:\/\/doi.org\/10.1200\/JCO.2012.45.2722","journal-title":"J Clin Oncol"},{"issue":"1","key":"3614_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/japplphysiol.00455.2016","volume":"124","author":"RV Clark","year":"2018","unstructured":"Clark RV, Walker AC, Miller RR, O\u2019Connor-Semmes RL, Ravussin E, Cefalu WT (2018) Creatine (methyl-d3) dilution in urine for estimation of total body skeletal muscle mass: accuracy and variability vs. MRI and DXA. J Appl Physiol 124(1):1\u20139. \n                    https:\/\/doi.org\/10.1152\/japplphysiol.00455.2016","journal-title":"J Appl Physiol"},{"issue":"4","key":"3614_CR54","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/jcsm.12180","volume":"8","author":"IJG Rutten","year":"2017","unstructured":"Rutten IJG, Ubachs J, Kruitwagen R, Beets-Tan RGH, Olde Damink SWM, Van Gorp T (2017) Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle 8(4):630\u2013638. \n                    https:\/\/doi.org\/10.1002\/jcsm.12180","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3614_CR55","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/jcsm.12221","volume":"8","author":"V Baracos","year":"2017","unstructured":"Baracos V (2017) Psoas as a sentinel muscle for sarcopenia: a flawed premise. J Cachexia Sarcopenia Muscle 8:527\u2013528","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"3614_CR56","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ncb1101-1014","volume":"3","author":"SC Bodine","year":"2001","unstructured":"Bodine SC, Stitt TN, Gonzales M, Kline WO, Stover GL, Bauerlain R, Zlotchenko E, Scrimgeour A, Lawrence JC, Yancopoulos DJG GD (2001) Akt.mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 3:1014\u20131019","journal-title":"Nat Cell Biol"},{"key":"3614_CR57","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1091\/mbc.01-12-0584","volume":"13","author":"AL Edinger","year":"2010","unstructured":"Edinger AL, Thompson CB (2010) Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol Biol Cell 13:2276\u20132288","journal-title":"Mol Biol Cell"},{"issue":"4","key":"3614_CR58","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1007\/s00520-016-3518-2","volume":"25","author":"V Crosby","year":"2017","unstructured":"Crosby V, D\u2019Souza C, Bristow C, Proffitt A, Hussain A, Potter V, Hennig I, O\u2019Connor R, Baracos V, Wilcock A (2017) Can body composition be used to optimize the dose of platinum chemotherapy in lung cancer? A feasibility study. Support Care Cancer 25(4):1257\u20131261. \n                    https:\/\/doi.org\/10.1007\/s00520-016-3518-2","journal-title":"Support Care Cancer"},{"issue":"2","key":"3614_CR59","doi-asserted-by":"publisher","first-page":"e0192124","DOI":"10.1371\/journal.pone.0192124","volume":"13","author":"A Iannessi","year":"2018","unstructured":"Iannessi A, Beaumont H, Hebert C, Dittlot C, Falewee MN (2018) Computer tomography-based body surface area evaluation for drug dosage: Quantitative radiology versus anthropomorphic evaluation. PLoS One 13(2):e0192124. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0192124","journal-title":"PLoS One"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3614-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T19:08:24Z","timestamp":1559761704000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3614-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["3614"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3614-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"15 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This research did not involve human subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal participant rights"}}]}}